Iterum declares completion of enrollment in sulopenem clinical trial
Category: #health  By Mateen Dalal  Date: 2019-12-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

Iterum declares completion of enrollment in sulopenem clinical trial
  • The clinical trial was aimed at the treatment of uncomplicated urinary tract infections.
  • The enrollment is expected to garner topline results in quarter one of 2020.

Ireland based Iterum Therapeutics has reportedly announced the completion of patient enrollment in its Sulopenem for Resistance Enterobacteriaceae 1, phase 3 clinical trial for uncomplicated urinary tract infections.

For the uninitiated, sulopenem is an innovative penem anti-infective compound with the oral formulations that has exhibited powerful in vitro activity against a vast range of gram negative and positive resistant to the other antibiotics.  

It has been claimed that the clinical trials across 1,670 patients would produce topline results in Q1 2020. Moreover, this multi-center, double-blind trial would measure the efficiency, tolerance, and safety of oral sulopenem for the treatment of uUTI in adult women, and other patients. The patients are randomized to receive either oral sulopenem two times a day for 5 days or are given oral ciprofloxacin twice daily for 3 days.

Speaking on the matter, the CEO of Iterum Therapeutics, Corey Fishman, reportedly quoted that the company is elated to announce the completion of enrollment of its final phase 3 clinical trial for the uUTI with over 1670 patients being treated. Additionally, the trial is expected to produce high quality results in the first quarter of 2020. Mr. Fishman further added that the launch of this new oral treatment fir urinary tract infections is first since a long time period of 20 years. On receiving the safety approval, oral sulopenem would offer an option to all those patients with an elevated risk for treatment failure.

For the records, Iterum Therapeutics is a pharmaceutical company which is focused on making next gen oral and IV antibiotics. Apparently, these antibiotics are used to treat the infections caused by multi-drug anti pathogens in all environments. The company has also received Qualified Infectious Disease Product and Fast Track designations for IV and oral formulations of the sulopenem drug in over seven indications.

Source credit: https://www.iterumtx.com/news/press-releases/detail/30/iterum-therapeutics-announces-completion-of-enrollment-in

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

DealerSocket closes acquisition of Auto/Mate to offer innovative DMS
DealerSocket closes acquisition of Auto/Mate to offer innovative DMS
By Mateen Dalal

DealerSocket, a customer relationship management solutions provider, has recently completed the acquisition of DMS provider Auto/Mate to offer an all-in-one innovative software for their dealerships. Auto/Mate is a leading company that develops and m...

EU and U.S. to partner to counter Huawei’s dominance on next-gen 5G
EU and U.S. to partner to counter Huawei’s dominance on next-gen 5G
By Mateen Dalal

The European Union and the United States are likely to partner to counter the increasing dominance of Chinese tech giant, Huawei Technologies on next generation 5G telecommunications technology. However, this partnership will reportedly only come int...

CytoDyn files Phase 2 basket trial for cancer antagonist Leronlimab
CytoDyn files Phase 2 basket trial for cancer antagonist Leronlimab
By Mateen Dalal

CytoDyn Inc., announced that it has submitted a Phase 2 protocol with the U.S. Food and Drug Administration (FDA) for a basket trial under its cancer IND. The company can instantly start enrollment in this trial to offer therapy for around 22 various...